Published in Lancet on September 08, 1979
Circulating and tissue angiotensin systems. J Clin Invest (1987) 2.16
Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol (1982) 1.23
Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J (Clin Res Ed) (1982) 1.18
Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. Br Med J (1980) 1.17
Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. Br J Clin Pharmacol (1982) 1.00
Biochemistry and pharmacology of the renin-angiotensin system. Drugs (1990) 1.00
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. Br J Clin Pharmacol (1984) 0.90
Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest (1985) 0.89
Controlled trial of enalapril in congestive cardiac failure. Br Heart J (1985) 0.87
Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs (1985) 0.85
Absence of blood-pressure lowering effect of captopril in anephric patients. Br Med J (1980) 0.81
Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors. Br J Clin Pharmacol (1989) 0.77
Angiotensin converting enzyme inhibition: a new therapeutic modality. Bull N Y Acad Med (1981) 0.76
Inhibitors of angiotensin I converting enzyme for treating hypertension. Br Med J (1980) 0.75
The effect of aliskiren on the renal dysfunction following unilateral ureteral obstruction in the rat. Int J Physiol Pathophysiol Pharmacol (2016) 0.75
Hormonal and blood pressure changes during converting enzyme inhibition by teprotide. Postgrad Med J (1981) 0.75
Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials? West J Med (1993) 0.75
Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust (2001) 2.71
Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function. J Am Coll Cardiol (1999) 2.09
Minimum effective dosage in the drug treatment of hypertension. N Z Med J (1990) 1.93
Lead and delta-aminolaevulinic acid dehydratase levels in mentally retarded children and in lead-poisoned suckling rats. Lancet (1970) 1.93
Dalteparin for deep venous thrombosis: a hospital-in-the-home program. Med J Aust (1998) 1.90
Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation (1998) 1.87
Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol (1982) 1.81
Use of radial artery applanation tonometry and a generalized transfer function to determine aortic pressure augmentation in subjects with treated hypertension. J Am Coll Cardiol (1998) 1.73
Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int (2006) 1.68
Evidence from cross circulation studies for a humoral mechanism in the natriuresis of saline loading. Proc Soc Exp Biol Med (1966) 1.61
A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta (1980) 1.58
Cross-circulation experiments on the mechanism of the natriuresis during saline loading in the dog. Circ Res (1967) 1.55
Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size. Clin Sci (Lond) (1998) 1.43
Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase. Br Heart J (1989) 1.39
Treatment of hypertension. N Z Med J (1989) 1.39
Risk factors for coronary heart disease in a self-referred population compared with a general population. Med J Aust (1989) 1.38
Comparison of angiotensin converting enzyme inhibitors captopril and MK421-diacid in guinea pig atria. Eur J Pharmacol (1982) 1.35
Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond) (2001) 1.27
Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab (2001) 1.24
Atrial natriuretic peptide in chronic heart failure in the rat: a correlation with ventricular dysfunction. Circ Res (1986) 1.23
Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab (2005) 1.21
Reduced osmotic thirst in healthy elderly men. Am J Physiol (1991) 1.20
Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol (1999) 1.19
The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric (2000) 1.18
Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Drugs (1984) 1.15
The relation of arterial pressure and plasma angiotensin II concentration. A change produced by prolonged infusion of angiotensin II in the conscious dog. Circ Res (1979) 1.15
Swapping health care systems. Whose grass is really greener? JAMA (1996) 1.15
The organ-specificity of ferritin in human and horse liver and spleen. Biochem J (1973) 1.12
Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Lond) (1996) 1.12
Erythroid toxicity of azathioprin. Macrocytosis and selective marrow hypoplasis. Q J Med (1975) 1.11
Vascular dysfunction and autonomic neuropathy in Type 2 diabetes. Diabet Med (2004) 1.10
Treatment of hypertension. N Z Med J (1989) 1.07
Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol (1990) 1.07
The influence of naloxone on the circulatory effects of captopril. Br J Clin Pharmacol (1984) 1.06
Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol (1983) 1.03
Isolation of renin granules from rat kidney cortex and evidence for an inactive form of renin (prorenin) in granules and plasma. Endocrinology (1976) 1.03
A comparison of chlorothiazide, chlorthalidone and cyclopenthiazide in the treatment of hypertension. Med J Aust (1973) 1.02
Radioimmunoassay for plasma antidiuretic hormone. J Endocrinol (1972) 1.02
Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man. Clin Sci (Lond) (1981) 1.01
Plasma catecholamines and the pressor response to Sar1-Ala8-angiotensin II in man. Clin Sci Mol Med (1977) 1.01
Enalapril and autonomic reflexes and exercise performance. J Hypertens Suppl (1983) 1.00
Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients. Clin Sci (Lond) (1981) 1.00
Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension. Clin Exp Pharmacol Physiol Suppl (1982) 0.99
Renin substrate in granules from rat kidney cortex. Biochem J (1976) 0.99
Metabolism of angiotensin II in sodium depletion and hypertension in humans. Circ Res (1972) 0.99
Effect of nifedipine on blood pressure and adrenocortical responses to trophic stimuli in humans. J Cardiovasc Pharmacol (1982) 0.98
Calcium antagonists and hormone release: effect of nifedipine on luteinizing hormone-releasing hormone and thyrotropin-releasing hormone-induced pituitary hormone release. J Clin Endocrinol Metab (1983) 0.98
Enalapril (MK421) activation in man: importance of liver status. Br J Clin Pharmacol (1985) 0.98
Vasopressin in circulatory control and hypertension. J Hypertens (1985) 0.98
Contribution of vasopressin to the maintenance of blood pressure during dehydration. Am J Physiol (1983) 0.97
Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands. Endocrinology (1990) 0.97
Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine. Br J Pharmacol (1999) 0.96
The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol (1975) 0.96
Neurohumoral responses to chronic myocardial infarction in rats. Circulation (1988) 0.95
Renin, angiotensin II, and adrenal corticosteroid relationships during sodium deprivation and angiotensin infusion in normotensive and hypertensive man. Circ Res (1972) 0.95
Inhibition of adenylate cyclase by angiotensin II in rat renal cortex. Endocrinology (1982) 0.95
-Aminolevulinic acid dehydrase activity in the blood of men working with lead alkyls. Br J Ind Med (1972) 0.94
Plasma renin levels and vascular complications in hypertension. Br Med J (1973) 0.94
Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. J Hypertens Suppl (1983) 0.94
Localization of endothelin receptors in rat kidney. Eur J Pharmacol (1989) 0.94
Acute renal haemodynamic and renin-angiotensin system responses to graded renal artery stenosis in the dog. J Physiol (1979) 0.94
Catecholamines in peripheral venous plasma in patients on chronic haemodialysis. Clin Sci Mol Med (1978) 0.93
Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol (2000) 0.93
Chronotropic effects of angiotensin I, angiotensin II, bradykinin and vasopressin in guinea pig atria. Eur J Pharmacol (1982) 0.92
Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet (1984) 0.92
Treatment of hypertension with angiotensin converting enzyme inhibitors. Clin Exp Pharmacol Physiol Suppl (1982) 0.92
Use of captopril in the diagnosis of renal hypertension. Aust N Z J Med (1981) 0.91
Vasopressin V1 and V2 receptors in diabetes mellitus. Am J Physiol (1994) 0.91
The role of Ca2+ stores in the muscarinic inhibition of the K+ current IK(SO) in neonatal rat cerebellar granule cells. J Physiol (2000) 0.91
Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report. N Z Med J (1983) 0.91
Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol (1982) 0.91
Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 0.90
Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol (1990) 0.90
Acute changes in blood pressure and vasoactive hormones after captopril in hypertensive patients. Clin Exp Pharmacol Physiol (1981) 0.90
A review of plasma renin measurements and their clinical significance. Aust N Z J Med (1971) 0.90
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. Br J Clin Pharmacol (1984) 0.90
Decreased cardiac beta-adrenergic receptors in deoxycorticosterone-salt and renal hypertensive rats. Circ Res (1979) 0.90
Biological significance of renin angiotensin immunization. Circ Res (1970) 0.90
Immunoreactive arginine-vasopressin in Brattleboro rat ovary. Nature (1984) 0.89
Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors. Lancet (1978) 0.89
Enalapril reduces the catecholamine response to exercise in patients with heart failure. Eur J Clin Pharmacol (1986) 0.89
Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Hypertens (1997) 0.89
Effects of oestrogen and progesterone on age-related changes in arteries of postmenopausal women. Clin Exp Pharmacol Physiol (1997) 0.88
Angiotensins I and II in renal vein blood. Kidney Int (1979) 0.88
Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibition. Kidney Int (1981) 0.88
Heart mass and blood pressure have separate genetic determinants in the New Zealand genetically hypertensive (GH) rat. J Hypertens (1995) 0.88
Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology (2001) 0.88
Localization of angiotensin converting enzyme in rat heart. Circ Res (1991) 0.88